The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms
Abstract
Statins, given to lower blood cholesterol, clearly reduce the risk of cardiovascular events and deaths in patients with and also those without a history of coronary artery disease. Previous trials have reported a 25% to 35% reduction in low-density lipoprotein (LDL) cholesterol. Current guidelines propose a target concentration of less than 100 mg/dL. The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial compared standard treatment (40 mg pravastatin daily) with more intensive treatment that lowers the LDL cholesterol to approximately 70 mg/dL. Participants were 4162 clinically stable patients aged 18 and older who had been hospitalized for an acute coronary syndrome (acute myocardial infarction with or without ST-segment elevation, high-risk unstable angina) in the past 10 days. Total blood cholesterol was no greater than 240 mg/dL. Using a double-blind design, the patients were randomly assigned to receive either 40 mg pravastatin or 80 mg atorvastatin daily. Dietary counseling was provided, and patients were seen every 4 months (mean follow up, 24 months). The primary outcome was the interval between randomization and death from any cause, myocardial infarction (MI), severe unstable angina, revascularization, or stroke. The 2 groups were well matched except for more peripheral artery disease in the pravastatin group. The most common index events were unstable angina and MI with or without ST-segment elevation. More than two thirds of patients had a percutaneous coronary artery intervention before randomization. After 30 days, the median LDL cholesterol in patients receiving a statin for the first time declined by 22% and 51%, respectively, in the pravastatin and atorvastatin groups. Rates of the primary end point at 2 years were 26% in the pravastatin group and 22.4% with high-dose atorvastatin therapy. A 16% reduction in the hazard ratio favored atorvastatin. The benefit gained from high-dose therapy was evident at 30 days and persisted over time. The risk of a secondary end point (coronary death, MI, revascularization) was reduced by 14% in patients given atorvastatin (17.7% vs. 22.3% in the pravastatin group). Comparable efficacy was found for men and women, for patients with MI, and for diabetics. A significant increase in serum alanine aminotransferase was noted in 1.1% of the pravastatin group and 3.3% of those given atorvastatin. Intensive statin therapy provides more protection against death or major cardiovascular events than does standard treatment in patients with a recent acute coronary syndrome. It could be that the target LDL cholesterol in these patients should be lower than that currently recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Cited by
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., Thuren, T., Glynn, R. J., Ridker, P. M., MacFadyen, J. G., Everett, B. M., Libby, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32814-3 · Cited by 919
The origins of age-related proinflammatory state
Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D. D., Guralnik, J. M., & Longo, D. L. (2005) · Blood · doi:10.1182/blood-2004-07-2599 · Cited by 908
Optimal low-density lipoprotein is 50 to 70 mg/dl
O'Keefe, J. H., Cordain, L., Harris, W. H., Moe, R. M., & Vogel, R. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.03.046 · Cited by 477
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Venue
- Obstetrical & Gynecological Survey
- Published
- 2004-07
- Volume
- 59
- Issue
- 7
- Pages
- 522-524
- ISSN
- 0029-7828 (ISSN-L)
- OpenAlex
- W2166615068
- Cited by
- 159
- References
- 4
- FWCI
- 34.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms. https://app.cochat.ai/papers/10.1097/00006254-200407000-00019
- The paper
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004). Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms. Obstetrical & Gynecological Survey. https://doi.org/10.1097/00006254-200407000-00019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.